Active Research Projects

Our research team is always looking for ways to improve the health of children. There are several clinical trials that are currently under way. For questions on our research operations, please contact Dennis Carson at 682-885-7491.

What type of research study are you looking for?

Find an active research study

16T-MC-AMBU(a) - A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients with Moderately to Severely Active Ulcerative Colitis. SHINE-1

Primary Investigator: Clifton Huang

IRB ID: 2019-081 (OPEN)

Study Information
Request Information
A Randomized Trial in 2 parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism?

Primary Investigator: Paul Stephen Thornton

IRB ID: 2019-087 (OPEN)

Study Information
Request Information
A Clinical and Molecular Risk-Detected Therapy for Newly Diagnosed Medulloblastoma (SJMB12)

Primary Investigator: Jeffrey C. Murray

IRB ID: 2014-025 (OPEN)

Study Information
Request Information
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Primary Investigator: Karen Halaburt Albritton

IRB ID: 2014-084 (OPEN)

Study Information
Request Information
A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in children and young adults with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) followed by long-term open-label treatment.

Primary Investigator: M. Scott Perry

IRB ID: 2018-090 (OPEN)

Study Information
Request Information
A Learning Healthcare System for Pediatric Epilepsy

Primary Investigator: M. Scott Perry

IRB ID: 2019-064 (OPEN)

Request Information
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Primary Investigator: Mary Suzanne Whitworth

IRB ID: 2015-061 (OPEN)

Study Information
Request Information
A Long-Term Non-InterventionalRegistry to Assess Safety and Effectiveness of Humira� (Adalimumab) in Pediatric Patients withModerately to Severely Active Crohn's Disease (CD).

Primary Investigator: Nicholas Ogunmola

IRB ID: 2015-052 (OPEN)

Study Information
Request Information
A Long-term Observational Study Evaluating Eteplirsen in Patients with Duchenne Muscular Dystrophy under Conditions of Routine Clinical Practice

Primary Investigator: Warren A. Marks

IRB ID: 2019-007 (OPEN)

Request Information
A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)

Primary Investigator: Karen Schultz

IRB ID: 2020-024 (OPEN)

Request Information
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Primary Investigator: Gretchen Eames

IRB ID: 2011-191 (OPEN)

Study Information
Request Information
A multicenter safety study of unlicensed, investigational, cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (�NCBP�) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

Primary Investigator: Gretchen Eames

IRB ID: 2015-077 (OPEN)

Study Information
Request Information
A multi-center study to describe the epidemiology, clinical presentation, and outcomes of pediatric patients with Covid-19 across the United States.

Primary Investigator: Mary Suzanne Whitworth

IRB ID: 2020-029 (OPEN)

Request Information
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE).

Primary Investigator: Kelly L. Vallance

IRB ID: 2020-014 (OPEN)

Study Information
Request Information
A natural history study of neonatal enteroviral sepsis, to identify endpoints for subsequent therapeutic studies with new drugs being developed by pharmaceutical companies.DMID 19-0026 Enteroviral Sepsis Natural History - Whitworth

Primary Investigator: Mary Suzanne Whitworth

IRB ID: 2020-031 (OPEN)

Request Information
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma

Primary Investigator: M. Meaghan Granger

IRB ID: 2020-018 (OPEN)

Study Information
Request Information
A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-002 (OPEN)

Study Information
Request Information
A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2019-063 (OPEN)

Study Information
Request Information
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Primary Investigator: M. Meaghan Granger

IRB ID: 2019-049 (OPEN)

Study Information
Request Information
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355))

Primary Investigator: Sibo Zhao

IRB ID: 2019-072 (OPEN)

Study Information
Request Information
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Primary Investigator: Kenneth M. Heym

IRB ID: 2017-049 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations

Primary Investigator: Jeffrey C. Murray

IRB ID: 2019-003 (OPEN)

Study Information
Request Information
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occlusive Crisis

Primary Investigator: Clarissa Johnson

IRB ID: 2019-024 (OPEN)

Study Information
Request Information
A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 as Adjunctive Therapy in Patients with RareEpilepsy

Primary Investigator: M. Scott Perry

IRB ID: 2019-029 (OPEN)

Study Information
Request Information
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irritable Bowel Syndrome with Diarrhea (IBS-D)

Primary Investigator: Bankole Osuntokun

IRB ID: 2018-026 (OPEN)

Study Information
Request Information
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlledStudy to Evaluate the Safety of MEDI8897, a MonoclonalAntibody With an Extended Half-life Against RespiratorySyncytial Virus, in High-risk Children (MEDLEY)

Primary Investigator: Karen Schultz

IRB ID: 2019-048 (OPEN)

Study Information
Request Information
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Primary Investigator: Sibo Zhao

IRB ID: 2020-011 (OPEN)

Study Information
Request Information
A Phase 3 Randomized Study of Selumetinib (IND #77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG))

Primary Investigator: Jeffrey C. Murray

IRB ID: 2019-075 (OPEN)

Study Information
Request Information
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Primary Investigator: Kenneth M. Heym

IRB ID: 2020-072 (OPEN)

Request Information
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Primary Investigator: Kenneth M. Heym

IRB ID: 2020-022 (OPEN)

Study Information
Request Information
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-030 (OPEN)

Study Information
Request Information
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Primary Investigator: Kenneth M. Heym

IRB ID: 2019-059 (OPEN)

Study Information
Request Information
A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Primary Investigator: Karen Schultz

IRB ID: 2018-053 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis

Primary Investigator: Karen Schultz

IRB ID: 2019-044 (OPEN)

Study Information
Request Information
A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to

Primary Investigator: Karen Schultz

IRB ID: 2020-009 (OPEN)

Study Information
Request Information
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in the Treatment of Pediatric Patients with Persistent Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

Primary Investigator: Gretchen Eames

IRB ID: 2020-047 (OPEN)

Request Information
A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia (BMS reference CA209-9JY)

Primary Investigator: Kenneth M. Heym

IRB ID: 2019-018 (OPEN)

Study Information
Request Information
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Primary Investigator: M. Meaghan Granger

IRB ID: 2016-078 (OPEN)

Study Information
Request Information
A Phase II Trial Of Epigenetic Priming In Patients With Newly Diagnosed Acute Myeloid Leukemia? ?

Primary Investigator: Kenneth M. Heym

IRB ID: 2017-031 (OPEN)

Study Information
Request Information
A Phase III Randomized Placebo Controlled Study to Examinethe Effects of DAS181 for the Treatment of Lower RespiratoryTract Parainfluenza Infection in Immunocompromised Subjects

Primary Investigator: Richard P. Howrey

IRB ID: 2019-012 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (tedizolid phosphate) and Comparator in Subjects from Birth to

Primary Investigator: Ana Maria Rios

IRB ID: 2018-024 (OPEN)

Study Information
Request Information
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT INHIBITORS

Primary Investigator: Donald Beam

IRB ID: 2020-048 (OPEN)

Request Information
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NOT PREVIOUSLY TREATED WITH COMPLEMENT INHIBITORS

Primary Investigator: Donald Beam

IRB ID: 2020-049 (OPEN)

Request Information
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo�) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

Primary Investigator: Kenneth M. Heym

IRB ID: 2016-075 (OPEN)

Study Information
Request Information
A point prevalence survey regarding antibiotic use in children for four two week blocks.

Primary Investigator: Marc A. Mazade

IRB ID: 2016-016 (OPEN)

Request Information
A Process Improvement Tool to Enhance and Monitor the Treatment of Children and Adolescents with Diabetic Ketoacidosis (DKA)

Primary Investigator: Don P. Wilson

IRB ID: 2013-045 (OPEN)

Request Information
A Prospective Data Registry for the Congenital Cardiovascular Interventional Study Consortium: Risk Stratification for Cardiac Catheterization Procedures

Primary Investigator: Duy Kuo

IRB ID: 2016-064 (OPEN)

Request Information
A prospective Study of Acute Flaccid Myelitis (AFM) to Define Natural History, Risk Factors, and Pathogenetic Mechanisms? ?

Primary Investigator: Lynne M. Eger

IRB ID: 2019-074 (OPEN)

Request Information
A prospective study to evaluate biological and clinical effects of significantly corrected CFTR function in infants and young children.?

Primary Investigator: Karen Schultz

IRB ID: 2020-052 (OPEN)

Request Information
A Prospective, Long Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy

Primary Investigator: Warren A. Marks

IRB ID: 2019-052 (OPEN)

Study Information
Request Information
A Randomised Phase 3 trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-089 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Primary Investigator: Kelly L. Vallance

IRB ID: 2019-101 (OPEN)

Study Information
Request Information
A Randomized, Double-Blind Evaluation of the Pharmacokinetics,Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) inAdolescents with Chronic Hepatitis B Virus Infection

Primary Investigator: Mary Suzanne Whitworth

IRB ID: 2016-091 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia" ?

Primary Investigator: Paul Stephen Thornton

IRB ID: 2020-039 (OPEN)

Request Information
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis (EoE)

Primary Investigator: Bankole Osuntokun

IRB ID: 2020-010 (OPEN)

Study Information
Request Information
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Primary Investigator: Paul Stephen Thornton

IRB ID: 2020-038 (OPEN)

Request Information
A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Primary Investigator: Kenneth M. Heym

IRB ID: 2019-036 (OPEN)

Study Information
Request Information
A Test of Children�s English/Spanish Speech Perception in Noise or Speech Maskers

Primary Investigator: Lisa Vaughan

IRB ID: 2019-040 (OPEN)

Request Information
AAML1531, Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Primary Investigator: Kenneth M. Heym

IRB ID: 2016-031 (OPEN)

Study Information
Request Information
Activa� Dystonia Therapy

Primary Investigator: Warren A. Marks

IRB ID: 593 (OPEN)

Study Information
Request Information
Allergan_Lin-MD 64_Osuntokun

Primary Investigator: Bankole Osuntokun

IRB ID: 2019-047 (OPEN)

Study Information
Request Information
Allergan_Lin-MD 66_Osuntokun

Primary Investigator: Bankole Osuntokun

IRB ID: 2019-086 (OPEN)

Study Information
Request Information
Allergan_Lin-MD 67_Osuntokun

Primary Investigator: Bankole Osuntokun

IRB ID: 2019-050 (OPEN)

Study Information
Request Information
ALTE03N1 - Key Adverse Events After Childhood Cancer

Primary Investigator: Donald Beam

IRB ID: 543 (OPEN)

Study Information
Request Information
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer

Primary Investigator: Jeffrey C. Murray

IRB ID: 2009-013 (OPEN)

Study Information
Request Information
ALTE1621, Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PReVent-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Primary Investigator: Donald Beam

IRB ID: 2017-005 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
An Open-label Study with a Nonrandomized Single-dosePhase in Subjects with Suspected or Confirmed AerobicGram-negative Bacterial Infections followed by aRandomized, Multiple-dose, Active-controlled Phase inSubjects with Suspected or Confirmed ComplicatedUrinary Tract Infection (cUTI), to Assess the Safety,Tolerability, and Pharmacokinetics of Cefiderocol inHospitalized Pediatric Subjects 3 Months to < 18 Years ofAge?

Primary Investigator: Lynne M. Eger

IRB ID: 2019-066 (OPEN)

Study Information
Request Information
An Expanded Access Protocol for Use of Triheptanoin in Patients with Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)

Primary Investigator: Adrian Lacy

IRB ID: 2019-027 (OPEN)

Request Information
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Primary Investigator: Paul Stephen Thornton

IRB ID: 2019-103 (OPEN)

Study Information
Request Information
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Primary Investigator: Richard P. Howrey

IRB ID: 2016-008 (OPEN)

Study Information
Request Information
An Observational Study to Investigate Cognition and Quality of Life in Children and Adolescents with Dravet Syndrome

Primary Investigator: M. Scott Perry

IRB ID: 2019-032 (OPEN)

Request Information
An Open-Label Extension Study Of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy

Primary Investigator: Warren A. Marks

IRB ID: 2019-084 (OPEN)

Study Information
Request Information
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Primary Investigator: Paul Stephen Thornton

IRB ID: 2020-045 (OPEN)

Request Information
An Open-Label Trial of Triheptanoin in Patients with Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)

Primary Investigator: Adrian Lacy

IRB ID: 2013-034 (OPEN)

Study Information
Request Information
An Open-label, Expanded Access Protocol for Pediatric Patients with Sickle Cell Disease Who Have No Alternative Treatment Options

Primary Investigator: Clarissa Johnson

IRB ID: 2020-085 (OPEN)

Request Information
An Open-Label, Expanded Access Protocol Using 131-I-Metaiodobenzylguanidine (131 I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Primary Investigator: M. Meaghan Granger

IRB ID: 2012-026 (OPEN)

Study Information
Request Information
An Open-label, Non-investigational Product, Multi-center, Lead-in Study to Evaluate Prospective Bleeding and Infusion Data of Current FVIII Replacement Therapy in Adult Males with Hemophilia A

Primary Investigator: Timothy McCavit

IRB ID: 2019-105 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
An?? NIH CSER program clinical sequencing study grant collaboration

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-058 (OPEN)

Request Information
ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in combination with Chemotherapy for Newly Diagnosed Patients with ALCL (IND#117117)

Primary Investigator: Kenneth M. Heym

IRB ID: 2015-007 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
APEC1621M: PHASE 2 SUBPROTOCOL OF TIPIFARNIB IN PATIENTS WITH TUMORS HARBORING HRASGENOMIC ALTERATIONS

Primary Investigator: Kelly L. Vallance

IRB ID: 2020-070 (OPEN)

Request Information
AREN1921

Primary Investigator: Kelly L. Vallance

IRB ID: 2020-097 (OPEN)

Request Information
Can we salvage young children with relapse medulloblastoma after initial radiation sparing approaches?

Primary Investigator: Jeffrey C. Murray

IRB ID: 2020-044 (OPEN)

Request Information
CASCADE FH Registry

Primary Investigator: Don P. Wilson

IRB ID: 2016-090 (OPEN)

Request Information
CCSS Childhood Cancer Survivor Study

Primary Investigator: Donald Beam

IRB ID: 2009-027 (OPEN)

Study Information
Request Information
Children�s Mercy Kansas City Cardiac High Acuity Monitoring Program (CHAMP).

Primary Investigator: Lisa M. Roten

IRB ID: 2017-033 (OPEN)

Request Information
Clinical Assessment of Flow in Tetralogy of Fallot by Time-Resolved Volumetric Phase Contrast MRI?

Primary Investigator: Steve Muyskens

IRB ID: 2015-047 (OPEN)

Request Information
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D).

Primary Investigator: Gretchen Eames

IRB ID: 2019-054 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
Clinical, Radiologic, And Molecular Characteristics Of Anaplastic Pleomorphic Xanthoastrocytomas

Primary Investigator: Sibo Zhao

IRB ID: 2020-063 (OPEN)

Request Information
CliniMACS� CD34+ T-cell Depletion of a Haploidentical Stem Cell Product as Part of a Treatment Protocol for Patients with Bone Marrow Failure

Primary Investigator: Richard P. Howrey

IRB ID: 2018-041 (OPEN)

Request Information
CNTO148UCO3003 A Phase 3 Randomized, Open Label Study to assess the efficacy, safety, and pharmacokinetics of Golimumab Treatment, a Human anti-TNFa Monoclonal Antibody, administered subcutaneously in pediatric participants with moderately to severely active Ulcerative Colitis

Primary Investigator: Bankole Osuntokun

IRB ID: 2018-099 (OPEN)

Study Information
Request Information
Cognitive and Neuroimaging Biosignatures of Well-being in Youth with and without Seizures

Primary Investigator: Crystal Cooper

IRB ID: 2020-104 (OPEN)

Request Information
Comparison Between Surgical versus Balloon Angioplasty versus Intravascular Stent Placement for Recurrent or Native Coarctation of the Aorta

Primary Investigator: Deborah A. Schutte

IRB ID: 2008-03 (OPEN)

Request Information
Comprehensive Epilepsy Center Surgical Database Project

Primary Investigator: M. Scott Perry

IRB ID: 2010-068 (OPEN)

Request Information
Cook Children�s Health Care System Stroke and Thrombosis Registry

Primary Investigator: Marcela D. Torres

IRB ID: 2020-037 (OPEN)

Request Information
Diagnosis and Treatment of Pediatric Strokes Before and After Implementation of a Pediatric Stroke Alert System at a Non-Academic Institution

Primary Investigator: Fernando Acosta Jr.

IRB ID: 2020-032 (OPEN)

Request Information
Domperidone Use in Patients with Gastrointestinal Disorders

Primary Investigator: Bankole Osuntokun

IRB ID: 2018-088 (OPEN)

Request Information
Early MRSA therapy in CF � Optimizing the Regimen (STaph Aureus Resistance-Treat Early and Repeat)

Primary Investigator: Karen Schultz

IRB ID: 2018-075 (OPEN)

Study Information
Request Information
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

Primary Investigator: Donald Beam

IRB ID: 2018-028 (OPEN)

Study Information
Request Information
ELX/TEZ/IVA Expanded Access Program for Patients 6 Through 11 Years of Age With Cystic Fibrosis Who Have At Least One F508del Mutation

Primary Investigator: Karen Schultz

IRB ID: 2021-003 (OPEN)

Request Information
Evaluation Of The Efficacy Of Reirradiation�in Locally Recurrent Ependymoma

Primary Investigator: Jeffrey C. Murray

IRB ID: 2018-021 (OPEN)

Request Information
Exploration of Perceived Stress, Sleep, Fatigue, and Biomarkers in Childhood Brain Tumor Survivors

Primary Investigator: Lisa M Bashore NP

IRB ID: 2018-010 (OPEN)

Request Information
Genzyme Rare Diseases Registry

Primary Investigator: Robert S. Gillespie

IRB ID: 2009-043 (OPEN)

Request Information
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy

Primary Investigator: Donald Beam

IRB ID: 2014-023 (OPEN)

Study Information
Request Information
Hyperinsulinism Center Registry for Research and Quality Data Collection

Primary Investigator: Paul Stephen Thornton

IRB ID: 2011-183 (OPEN)

Request Information
Ictal and Interictal High-Frequency Electrophysiological Activity for the Localization of the Epileptogenic Zone in Children with Refractory Epilepsy

Primary Investigator: Christos Papadelis PhD

IRB ID: 2019-070 (OPEN)

Request Information
Improve Care Now

Primary Investigator: Nicholas Ogunmola

IRB ID: 2013-014 (OPEN)

Request Information
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Primary Investigator: Kenneth M. Heym

IRB ID: 2017-048 (OPEN)

Study Information
Request Information
International Registry for Severe Chronic Neutropenia

Primary Investigator: Donald Beam

IRB ID: 94 (OPEN)

Study Information
Request Information
Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study

Primary Investigator: David Riley

IRB ID: 2015-001 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

Primary Investigator: M. Meaghan Granger

IRB ID: 2018-048 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma

Primary Investigator: Karen Halaburt Albritton

IRB ID: 2015-006 (OPEN)

Study Information
Request Information
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Primary Investigator: M. Meaghan Granger

IRB ID: 2010-109 (OPEN)

Study Information
Request Information
MIBG 2014-01, A Phase II Single-Arm Study of Therapeutic Iobenguane (131I) for High-Risk Neuroblastoma Subjects at the Time of First Relapse

Primary Investigator: M. Meaghan Granger

IRB ID: 2018-079 (OPEN)

Study Information
Request Information
MOVR Data Hub

Primary Investigator: Warren A. Marks

IRB ID: 2019-055 (OPEN)

Study Information
Request Information
Multi Center iMRI Neurosurgery Database

Primary Investigator: John Honeycutt

IRB ID: 2013-025 (OPEN)

Request Information
Multi-center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolimide as a Second-Line Regimen for Ewing's Sarcoma

Primary Investigator: Anish K. Ray

IRB ID: 2019-005 (OPEN)

Study Information
Request Information
Multi-modal neuroimaging in children with cerebral palsy to assess functional and anatomical reorganization in relation to sensory and motor functions

Primary Investigator: Christos Papadelis PhD

IRB ID: 2019-068 (OPEN)

Request Information
NANT 2013-01: Immunotherapy of Relapsed Neuroblastoma with Expanded NK Cells, Lenalidomide, and ch14.18

Primary Investigator: M. Meaghan Granger

IRB ID: 2018-050 (OPEN)

Study Information
Request Information
NANT 2015-02: Phase 1 Study of Lorlatinib (PF-06463922), An Oral Small Molecula Inhibitor of ALK/ROS1, for Patients with ALK-Driven Relapsed or Refractory Neuroblastoma

Primary Investigator: M. Meaghan Granger

IRB ID: 2017-022 (OPEN)

Study Information
Request Information
NANT 2017-01: A Phase I Study of 131I-MIBG with Dinutuximab for Relapsed/Refractory Neuroblastoma

Primary Investigator: M. Meaghan Granger

IRB ID: 2018-032 (OPEN)

Study Information
Request Information
National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) - A Collaborative Initiative to Improve Care of Children with Complex Congenital Heart Disease

Primary Investigator: Lisa M. Roten

IRB ID: 2017-032 (OPEN)

Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR alterations

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-008 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of LOXO-101 (Larotrectinib) in patients with tumors harboring NTRK fusions.

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-006 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of Olaparib in patients with tumors harboring defects in DNA damage repair genes

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-007 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of Tazemetostat in patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-005 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice) - Phase 2 Subprotocol Of Palbociclib In Patients With Tumors Harboring Activating Alterations In Cell Cycle Genes

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-068 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-003 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of LY3023414 in patients with solid tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-009 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Selumetinib in patients with tumors harboring activating MAPK pathway mutations

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-066 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Vemurafenib in patients with tumors harboring BRAF V600 mutations

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-004 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-065 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)-Phase 2 Subprotocol Of BVD-523FB (Ulixertinib) In Patients With Tumors Harboring Activating Mapk Pathway Mutations

Primary Investigator: Kelly L. Vallance

IRB ID: 2019-102 (OPEN)

Study Information
Request Information
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and serum Cystatin C levels in children after Cardiopulmonary Bypass (CPB)

Primary Investigator: James D. Marshall

IRB ID: 2020-041 (OPEN)

Request Information
Observational study in infants and children with SCN1A+ Dravet Syndrome

Primary Investigator: M. Scott Perry

IRB ID: 2020-056 (OPEN)

Request Information
Parental Attitudes in Neonatal Clinical Trial Enrollment:Decision-Making Preferences and Reasoning among Participants and Non-Participants

Primary Investigator: David Riley

IRB ID: 2017-016 (OPEN)

Request Information
Participation in the Cystic Fibrosis Patient Registry

Primary Investigator: Karen Schultz

IRB ID: 394 (OPEN)

Request Information
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Primary Investigator: Lauren Akers

IRB ID: 2018-066 (OPEN)

Study Information
Request Information
Pediatric International DBS (PEDiDBS) Registry

Primary Investigator: Warren A. Marks

IRB ID: 2016-013 (OPEN)

Request Information
PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONS

Primary Investigator: Kelly L. Vallance

IRB ID: 2020-055 (OPEN)

Study Information
Request Information
Phase I Dravet Syndrome study in Children and Adolescents

Primary Investigator: M. Scott Perry

IRB ID: 2020-012 (OPEN)

Request Information
Prospective validation of a pediatric venous thrombosis risk prediction model using the CHAT: A Multi-Institutional Children�s Hospital-Acquired Thrombosis Registry

Primary Investigator: Marcela D. Torres

IRB ID: 2020-016 (OPEN)

Request Information
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Primary Investigator: Gretchen Eames

IRB ID: 2019-061 (OPEN)

Study Information
Request Information
Protocol for a Research Sample Repository for Hematopoietic Cell Tranplantation, Other Cellular Therapies, and Marrow Toxic Injuries

Primary Investigator: Gretchen Eames

IRB ID: 2019-062 (OPEN)

Study Information
Request Information
Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

Primary Investigator: Christos Papadelis PhD

IRB ID: 2019-085 (OPEN)

Request Information
Randomization of Cytarabine Monotherapy versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis

Primary Investigator: Anish K. Ray

IRB ID: 2019-067 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
RBDD-PLG Project; International Retrospective and Prospective Study of Individuals affected with Hypoplasminogenemia

Primary Investigator: Marcela D. Torres

IRB ID: 2019-028 (OPEN)

Study Information
Request Information
Survey of the National Lipid Association�s Membership - Opinions of the 2011 National Heart, Lung and Blood Institute�s Expert Panel Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents.

Primary Investigator: Don P. Wilson

IRB ID: 2013-028 (OPEN)

Request Information
Testicular tissue cryopreservation for fertility preservation in patients facing infertility-causing diseases or treatment regimens

Primary Investigator: Blake W. Palmer

IRB ID: 2020-053 (OPEN)

Request Information
The American Thrombosis and Hemostasis Network (ATHN) National Web Tracker

Primary Investigator: Timothy McCavit

IRB ID: 2011-160 (OPEN)

Study Information
Request Information
The �HEAL� Study, High-Dose Erythropoietin for Asphyxia and Encephalopathy (A randomized, placebo-controlled, double-masked 500-subject clinical trial of erythropoietin for the treatment of neonatal hypoxic-ischemic encephalopathy)

Primary Investigator: David Riley

IRB ID: 2017-010 (OPEN)

Study Information
Request Information
The Use of Fluorodopa 18F Positron Emission Tomography Combined with Computed Tomography in Congenital Hyperinsulinism

Primary Investigator: Paul Stephen Thornton

IRB ID: 2012-060 (OPEN)

Study Information
Request Information
Total Therapy Study XVII For Newly Diagnosed Patients With Acute Lymphoblastic Leukemia And Lymphoma

Primary Investigator: Kenneth M. Heym

IRB ID: 2018-080 (OPEN)

Study Information
Request Information
Towards the Establishment of Standards of Practice and the Inititation of Multi-Center, Multi-National Clinical Trials for Neonates and Children with Stroke

Primary Investigator: Marcela D. Torres

IRB ID: 2012-008 (OPEN)

Study Information
Request Information
Use of Oxandrolone to Promote Growth in Infants with Hypoplastic Left Heart Syndrome: A Phase I/II Pilot Study

Primary Investigator: Phillip Burch

IRB ID: 2019-014 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Primary Investigator: M. Meaghan Granger

IRB ID: 2015-032 (OPEN)

Study Information
Request Information
UX007 Triheptanoin GLUT1 DS EAP

Primary Investigator: Adrian Lacy

IRB ID: 2020-028 (OPEN)

Request Information
Vascular effects of Infection in Pediatric Stroke Study IIVIPS II

Primary Investigator: Marcela D. Torres

IRB ID: 2018-018 (OPEN)

Request Information
Venetoclax EAP IND 152442

Primary Investigator: Kenneth M. Heym

IRB ID: 2020-080 (OPEN)

Request Information